| INTRODUCTION
Papillary thyroid carcinoma (PTC) is one of the more commonly encountered metastatic carcinomas in FNA of cervical lymph nodes.
Most patients with PTC present with regional lymph node metastases 1,2 and about two-thirds of PTC recurrences occur in the neck, mostly in lymph nodes. 3 PTC may also present as an enlarged lateral neck node with no known primary tumour in up to 10% of cases. 4 When diagnostic material is adequate, the cytodiagnosis is usually straightforward with most metastatic PTC displaying characteristic morphology that mirrors that of primary PTC. 5 However, in some cases, immunohistochemical (IHC) staining of FNA material can be helpful in confirming thyroid as the primary site for a malignancy or as part of a panel that can help to exclude a thyroid primary.
Although several markers are available, none of those in current use are ideal. Cases were evaluated as positive if more than 5% of malignant cell stained. For TPO stained sections, the proportion of positive cells was also recorded as: negative (<5%); + (>5%<25%); ++ (>25%<50%); +++ (>50<75%) or ++++ (>75%).
| RESULTS
TPO staining was negative in all of the non-thyroid malignancies (Table 2) majority of patients present with either macro-or micrometastases. 1,2,10 PTC may also present with an occult primary. 4 It is the fourth most common type of metastasis from unknown primary tumours to present in cervical and supraclavicular lymph nodes. Tg has been used as a marker for thyroid carcinoma for many years. 16, 17 It has high sensitivity and specificity for thyroid carcinomas, being expressed in more than 95% of papillary and follicular carcinomas. Staining is usually reduced in poorly differentiated carcinoma and absent from anaplastic carcinoma. 18, 19 However, the stain is prone to technical issues and the extracellular, cytoplasmic and focal nature of staining may make interpretation difficult. 15, 19 Staining may also occur in sinus histiocytes of lymph nodes. 20 Measurement of Tg in needle washouts has also been applied as a method of confirming metastatic PTC malignancy in lymph nodes.
The method has been shown to be useful in cystic nodes evaluated as part of preoperative investigation of patients with PTC, particularly when cyst contents only are aspirated. However, interpretation of results is not always clear as there is no standardization of FNATg procedures or assays 21 and false positive results may occur, particularly in lymph nodes in the central compartment when the thyroid is still present. 22 Additionally, serum anti-Tg antibodies may interfere with FNA-Tg measurements and thereby result in falsely low FNA-Tg levels. 23 The method also requires dedication of at least some of the specimen to the assay rather than to the manufacture of a cell block, thus potentially limiting the application of further markers.
TTF-1 has been preferred to Tg recently as it has been shown to have high sensitivity and, being a nuclear stain, is easier to interpret.
TTF-1 is positive in 96% of PTC. 24 Compared with Tg, TTF-1 is more sensitive for follicular carcinomas, poorly differentiated carcinomas and metastatic lesions. 25 It is also more likely to stain medullary carcinoma. However, TTF-1 is also expressed in most lung | 229 adenocarcinomas and small cell carcinomas. Thus, staining of metastatic carcinoma cells with TTF-1 alone does not discriminate between these two primary sites and may even lead to misdiagnosis. 26 PAX-8 has also been used in IHC panels to identify thyroid carcinoma as it has not been found in lung carcinoma. 15 However it has a wide specificity, being expressed in renal cell carcinoma and M€ ullerian tumours, 19 including serous carcinoma which may share cytomorphological similarities with PTC in lymph node aspirates. 27 TPO is a thyroid-specific enzyme involved in the synthesis of thyroid hormone. It shows some relationship to differentiation and is down-regulated in malignancy. TPO mRNA is underexpressed in most PTC and some follicular carcinomas and IHC staining reduced or lost. 28 Most of the attention regarding its IHC use has focused on its role as a marker for malignancy in primary thyroid lesions, 6, 7 including in FNA specimens. 8 Several studies have examined whether reduced expression of TPO (staining in less than 80%, or 50%, of neoplastic cells) is indicative of malignancy. [6] [7] [8] Results have been inconsistent with several authors concluding that underexpression of TPO is not consistently or sufficiently linked to malignancy to justify its use in this role. 19, [29] [30] [31] Some of this variability may reflect the antibody used and the tissue examined. 28, 31 Our findings suggest that the addition of TPO (mAb EP159) to a panel of stains including TTF-1 may provide specific identification of a majority of metastatic PTCs in cervical lymph nodes. To the best of our knowledge, the use of TPO in this application has not previously been reported. 28, 30 Similarly, a limited number of cases were stained in the current study; however, as reported by others, 19, 30 we found TPO staining to be negative in a majority of medullary carcinomas and in the single case of anaplastic thyroid cancer.
In conclusion, the results of this study suggest that TPO (mAb EP159) may be a useful addition to IHC panels for FNA specimens where metastatic PTC is a consideration, particularly in cases where lung carcinoma features in the differential diagnosis.
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